Keywords: Gilead, GSK, GlaxoSmithKline, hepatitis B, Viread

Gilead and GlaxoSmithKline to commercialize Viread for chronic hepatitis B in key Asian countries; update on Avodart

Article | 26 November 2009

Print This

The USA’s Gilead Sciences and UK drug giant GlaxoSmithKline have signed a licensing agreement to commercialize the former’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in